How Much Does Vyleesi Cost in Illinois in 2026?

Brand-Name Vyleesi Pricing in Illinois

The manufacturer list price for Vyleesi remains $1,200 per month in 2026, and Illinois retail pharmacies match this figure almost exactly for cash-pay patients. Each carton contains four single-use autoinjectors delivering 1.75 mg bremelanotide subcutaneously [1]. The FDA approved bremelanotide in June 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [2].

This pricing places Vyleesi among the more expensive on-demand treatments for female sexual dysfunction. For context, the RECONNECT phase III program (two trials, combined N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events and a clinically meaningful reduction in distress compared to placebo over 24 weeks [3]. The FDA's prescribing information specifies a maximum of 8 doses per month, meaning the per-dose cost for brand-name Vyleesi works out to roughly $150 per use at full retail [2].

Illinois has no state-level drug pricing cap that applies to Vyleesi specifically. Patients paying out of pocket at chain pharmacies (CVS, Walgreens, Rite Aid locations throughout Chicago, Springfield, and downstate Illinois) will encounter the same $1,200 figure unless a discount program applies [1].

Illinois Medicaid Coverage for Vyleesi

Illinois Medicaid does cover Vyleesi, but requires prior authorization (PA). The PA process typically requires documentation that the patient has a formal HSDD diagnosis meeting DSM-5 criteria, has tried at least one behavioral or counseling intervention, and has no contraindicated conditions including uncontrolled hypertension [2]. The Endocrine Society's clinical practice guidelines on female sexual dysfunction support pharmacotherapy when behavioral interventions prove insufficient [4].

Processing time for Illinois Medicaid PA requests averages 3 to 5 business days. Prescribers should include the following in their PA submission: confirmed premenopausal status, documentation of distress using a validated instrument such as the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), and a blood pressure reading confirming systolic <140 mmHg and diastolic <90 mmHg [3][5].

Denial rates for Vyleesi PA requests run higher than average across Medicaid formularies nationally. A 2023 analysis of Medicaid formulary access published in the Journal of Women's Health found that only 58% of state Medicaid programs covered any FDA-approved HSDD treatment without significant restrictions [6]. Illinois falls in the "covered with PA" category, placing it ahead of states that exclude Vyleesi entirely.

Compounded Bremelanotide in Illinois: Legality and Cost

Compounded bremelanotide is legal in Illinois through licensed 503A pharmacies. These pharmacies operate under federal law (the Drug Quality and Security Act, Section 503A) and Illinois state pharmacy regulations, compounding patient-specific prescriptions based on a valid prescriber-patient relationship [7]. The cost averages $140 per month, representing an 88% reduction compared to brand-name Vyleesi.

Illinois does not maintain a "do not compound" list that includes bremelanotide. The drug is not on the FDA's Demonstrable Difficulty list, and no current FDA enforcement action restricts 503A compounding of bremelanotide [7]. Patients should verify that their chosen compounding pharmacy holds a valid Illinois Department of Financial and Professional Regulation pharmacy license and compounds under appropriate sterility standards (USP 797 compliance for injectable preparations) [8].

The compounded version is typically dispensed as a multi-use vial requiring the patient to draw up individual doses with an insulin syringe, rather than the pre-filled autoinjector format of brand-name Vyleesi. Dose standardization at 1.75 mg per injection mirrors the FDA-approved dosing [2]. Some Illinois 503A pharmacies also offer pre-filled syringes at a modest upcharge ($160 to $180 per month).

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for Vyleesi in Illinois varies significantly by plan and carrier. Blue Cross Blue Shield of Illinois, the state's largest commercial insurer, covers Vyleesi on select plans with step therapy and PA requirements. United Healthcare and Aetna plans sold in Illinois typically classify Vyleesi as a specialty medication on Tier 4 or Tier 5, resulting in copays ranging from $75 to $250 per month after PA approval [1].

The RECONNECT trials established the efficacy threshold that most insurers reference when setting coverage criteria: a statistically significant 0.5-increase in satisfying sexual events per month over placebo, with a Number Needed to Treat of approximately 5 to 6 for a clinically meaningful response [3]. Insurers generally require failure of, intolerance to, or contraindication for flibanserin (Addyi) before approving Vyleesi, since flibanserin received FDA approval four years earlier and carries a lower acquisition cost [9].

For patients with high-deductible health plans, Vyleesi's $1,200 monthly cost applies entirely to the deductible until it is met. The Palatin Technologies savings card (discussed below) cannot be combined with government-funded insurance programs including Medicaid, Medicare, or TRICARE, per federal anti-kickback statute requirements [10].

The Palatin Technologies Savings Card

Palatin Technologies offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 for the first fill and $50 per month thereafter, subject to an annual maximum benefit of $6,000 [1]. The card is valid at Illinois pharmacies that stock brand-name Vyleesi.

Eligibility requirements: the patient must have commercial insurance (not government-funded), be 18 years or older, and have a valid prescription for Vyleesi. The card works at point of sale. Activation requires enrollment through the manufacturer's patient support website or by phone [1].

For uninsured Illinois patients, the savings card does not apply. Uninsured patients face the full $1,200 retail price unless they access compounded bremelanotide or qualify for Palatin's separate patient assistance program, which provides free medication to patients meeting income thresholds (typically below 300% of the federal poverty level) [10].

Telehealth Prescribing of Vyleesi in Illinois

Illinois permits telehealth prescribing of Vyleesi without an in-person visit. The Illinois Telehealth Act (Public Act 102-0104) established parity for telehealth services, and the Illinois Medical Practice Act does not require an in-person examination before prescribing bremelanotide [11]. This means patients in rural downstate Illinois communities without local sexual medicine specialists can access treatment through video or audio-visual telehealth consultations.

The prescribing clinician must document blood pressure assessment (patient-reported home readings are generally accepted for telehealth encounters) since bremelanotide carries a labeled risk of transient hypertension [2]. The FDA label reports mean peak systolic blood pressure increases of 6 mmHg and diastolic increases of 3 mmHg occurring approximately 2 to 3 hours post-injection, resolving within 12 hours [2][5].

Multiple telehealth platforms serve Illinois patients seeking Vyleesi prescriptions. The prescription can be sent electronically to any licensed Illinois pharmacy, including 503A compounding pharmacies, and mail-order specialty pharmacies [11].

Clinical Considerations Affecting Cost Decisions

The choice between brand-name Vyleesi and compounded bremelanotide involves tradeoffs beyond price. The RECONNECT trial data supporting FDA approval specifically used the 1.75 mg autoinjector formulation [3]. No published trials have evaluated compounded bremelanotide in multi-use vial format, though the active pharmaceutical ingredient and dose are identical.

Blood pressure monitoring matters regardless of source. The FDA label carries a boxed warning about the risk of transient hypertension, and the prescribing information contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease [2]. Nausea is the most common adverse event, occurring in 40% of patients in the RECONNECT trials versus 1% with placebo [3][5].

The American College of Obstetricians and Gynecologists (ACOG) recognizes bremelanotide as an FDA-approved option for HSDD in premenopausal women, noting that both pharmacologic and non-pharmacologic approaches may be appropriate depending on patient preference and clinical context [12]. ACOG does not distinguish between brand and compounded formulations in its practice guidance.

Patients with hepatic impairment (Child-Pugh B or C) should avoid bremelanotide due to reduced clearance documented in pharmacokinetic studies [2]. The melanocortin receptor mechanism of action (MC4R agonism in the central nervous system) means bremelanotide works through a distinct pathway from flibanserin's 5-HT1A agonism, making it an option for patients who failed flibanserin therapy [9][13].

How to Minimize Vyleesi Cost in Illinois

The lowest-cost pathway depends on insurance status. For commercially insured patients: activate the Palatin savings card, confirm PA approval, and fill at an in-network specialty pharmacy. Expected cost: $0 to $50 per month [1].

For Illinois Medicaid enrollees: submit PA documentation through your prescriber, expect 3 to 5 business day processing, and fill at any Medicaid-participating pharmacy. Expected cost: $0 to $3 copay depending on your specific Medicaid managed care plan [10].

For uninsured or underinsured patients: request a prescription for compounded bremelanotide 1.75 mg/0.3 mL subcutaneous injection from a licensed Illinois 503A pharmacy. Expected cost: $140 per month [7]. Verify the pharmacy compounds under USP 797 sterile compounding standards and holds appropriate state licensure [8].

Patients using 4 or fewer doses per month may find that brand-name Vyleesi pricing becomes more manageable when the savings card applies, as the per-dose economics shift favorably at lower utilization rates. The FDA-approved maximum of 8 doses per month represents the upper ceiling, not a target [2][14].